Roivant Sciences Ltd. (ROIV): David Einhorn Trims Stake

We just covered 15 Under-the-Radar Picks from David Einhorn That Are Quietly Dominating 2026 and Roivant Sciences Ltd. (NASDAQ:ROIV) ranks 7th on this list.

Roivant Sciences Ltd. (NASDAQ:ROIV) has been a consistent feature in the 13F portfolio of Greenlight Capital since the first quarter of 2024. Back then, this position comprised 4.1 million shares. By the third quarter of 2024, the fund had grown this holding to 5.3 million shares. After the first quarter of 2025, the fund started trimming this stake. Filings for the fourth quarter of 2025 show that the fund owned a little over 2 million shares in the firm, down close to 10% compared to filings for the third quarter of 2025. Roivant is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of medicines.

How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform

Roivant Sciences Ltd. (NASDAQ:ROIV) recently announced a $2.25 billion global settlement with Moderna regarding COVID-19 vaccine patents. This non-dilutive capital injection has significantly bolstered the balance sheet of the firm. Beyond the lead candidates, hedge funds are also focused on the IMVT-1402 and Batoclimab programs of the firm. In April, Roivant released positive Phase 3 results for Batoclimab in Thyroid Eye Disease. Analysts note that the unique positioning of IMVT-1402, an investigational anti-FcRn antibody, in the auto-immune market gives the firm a structural advantage over competitors like Argenx.

While we acknowledge the risk and potential of ROIV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ROIV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT15 Safe Stocks to Invest In For Beginners and 10 Best Stocks to Buy According to Nancy Pelosi.

Disclosure: None. Follow Insider Monkey on Google News.